Video

Urologist Dr. Terrence Regan discusses prior authorization

Author(s):

Urology Times staff

“[Prior authorization has] become part of our everyday practicing life, but it does very little to advance quality of care,” says Terrence Regan, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Terrence Regan, MD, discusses his experience with obtaining prior authorizations. Regan is a urologist with Advanced Urology Institute in Palm Coast, Florida and serves as chair of the American Association of Clinical Urologists’ Health Policy Committee.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
      Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
      Mina Fam, MD, on managing expectations around testosterone replacement therapy
      Mina Fam, MD, on managing expectations around testosterone replacement therapy
      Justin Dubin, MD, on the role for AI in patient education
      Justin Dubin, MD, on the role for AI in patient education
      Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
      Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Justin Dubin, MD, on the use of AI in the male infertility space
      Justin Dubin, MD, on the use of AI in the male infertility space
      Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
      Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Investigators compare trimodal therapy vs cystectomy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Investigators assess ctDNA’s role in NMIBC
      Related Content
      US Capitol building | Image Credit: © sherryvsmith - stock.adobe.com
      May 6th 2025

      AUA Advocacy Summit: Medicare payment reform among top priorities

      Jennifer Miles-Thomas, MD, URPS, MBA Benjamin P. Saylor
      Jennifer Miles-Thomas, MD, URPS, MBA, discusses the AUA's legislative priorities along with issues in medicine related to artificial intelligence.
      Lawmaker stands at podium | Image Credit: © ckybe - stock.adobe.com
      May 4th 2025

      Health policy expert highlights the importance of state-level urology advocacy

      Benjamin P. Saylor
      "Developing a relationship with your legislator is just as important at the state level as it is at the federal level," says Hans Arora, MD, PhD.
      Biomarkers in urology: Policy and legislative advances
      April 22nd 2025

      Biomarkers in urology: Policy and legislative advances

      Ron Lanton, Esq
      "The AACU has been discussing the evolution of state policy to ensure that biomarker testing, including PSA screening, is covered by payers," writes Ron Lanton, Esq.
      House passes bill that includes 57% budget cut to medical research programs
      March 12th 2025

      House passes bill that includes 57% budget cut to medical research programs

      Hannah Clarke
      This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.
      Data refute concerns about telehealth as Congress weighs legislation
      March 7th 2025

      Data refute concerns about telehealth as Congress weighs legislation

      Hannah Clarke
      “Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its future," says Chad Ellimoottil, MD, MS.
      Enzalutamide included in next round of Medicare drug price negotiations
      January 17th 2025

      Enzalutamide included in next round of Medicare drug price negotiations

      Hannah Clarke
      The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.
      © 2025 MJH Life Sciences

      All rights reserved.